Market Research Logo

Rare Inflammatory Disease Treatment Market: Global Industry Analysis (2012-2016) & Opportunity Assessment (2017-2026)

Rare Inflammatory Disease Treatment Market: Global Industry Analysis (2012-2016) & Opportunity Assessment (2017-2026)

Innovative treatments are being developed by researchers, who are mainly focusing on reducing inflammation by using immunosuppressive therapies. Although these treatments promise remission in patients, risk of complications or relapse from long-lasting therapy prevail as key concerns. Significant improvements in the healthcare industry will stimulate in dealing with the rising instances regarding rare inflammatory diseases. Factors such as public health issues, antimicrobial resistance and unhygienic conditions are highly responsible for the prevalence of rare inflammatory disease. According to recent survey, nearly 200,000 patients suffer from more than 150 rare inflammatory diseases worldwide, which are also termed as ‘orphan diseases’. Out of these 150 orphan diseases, most of them are terminal and incurable.

Manufacturers are making heavy investments in R&D for developing new drugs for the rare inflammatory diseases. Technological advancements in equipment as well as procedures are likely to enable researchers to make improvements in diagnosing, treatment, and prevention of rare inflammatory diseases. As majority of rare diseases do not have effective treatment, researchers and pharmaceutical & medical companies are taking robust efforts toward new drug development as well as making advancements in currently employed drug formulations. The NIH (National Institutes of Health) is also supporting towards health improvement of affected and non-affected public with rare inflammatory diseases by focusing on new treatments. These institutes are providing support through collaborative projects which would help in examining common causes and themes of related diseases. According to recent report by Future Market Insights, the global market for rare inflammatory disease treatment is poised to grow at 4.4% CAGR during the review period, 2017-2026. The report evaluates that by 2026-end, around US$ 16,000 Mn rare inflammatory disease treatment products will be sold across the globe. The report additionally expects that North America will be leading the global rare inflammatory disease treatment market, in terms of revenues.

Juvenile Rheumatoid Arthritis to Gain Traction Through 2026

Juvenile rheumatoid arthritis is experienced by children at the age or less than 16years and the symptoms include stiffness, pain or tenderness on affected joints, abnormal warmth and swelling. In acute cases, critical changes may ultimately result in restricted mobility and potential deformity of concerned joints. Low prices of juvenile rheumatoid arthritis treatments will influence the producers to increase their manufacturing for advanced drugs and therapies. The report anticipates that juvenile rheumatoid arthritis will exhibit the highest CAGR over the forecast period.

Retail Pharmacies Distribution Channel of Rare Inflammatory Disease Treatment to Register Highest Value CAGR through 2017-2026

The increasing patient-centric support from retail pharmacies is leading to exceptional and consistent service levels in pharmacies. Several highly-skilled retail pharmacies are also available 24/7 in order to meet the needs of the patients. Retail pharmacies are also taking efforts in increasing availability of physicians in each pharmacy for better efficiency and to increase consumer demand. The report anticipates that by 2026-end, nearly 39.4% of rare inflammatory disease treatment expenditure will be held up by retail pharmacies across the globe.

Global Rare Inflammatory Disease Treatment Market

Companies leading the global rare inflammatory disease treatment market have been profiled by the analysts in the report. They include Novartis AG, Abbvie, Abbott Laboratories, Regeneron Pharmaceuticals, Swedish Orphan Biovitrum AB, Pfizer, Inc., Allergan Plc, Valeant, Johnson & Johnson and Questcor Pharmaceuticals, Inc. Some of these companiesare likely to cope with challenges through development of cost-effective treatments and advanced drugs. In addition, reducing production costs and raising profit margins will be a key focus area for players in the global rare inflammatory disease treatment market.


1. Global Economic Outlook
2. Global Rare Inflammatory Disease Treatment Market - Executive Summary
3. Global Rare Inflammatory Disease Treatment Market Overview
3.1. Introduction
3.1.1. Global Rare Inflammatory Disease Treatment Market Taxonomy
3.1.2. Global Rare Inflammatory Disease Treatment Market Definition
3.2. Global Rare Inflammatory Disease Treatment Market Size (US$ Mn) and Forecast, 2012-2026
3.2.1. Global Rare Inflammatory Disease Treatment Market Y-o-Y Growth
3.3. Global Rare Inflammatory Disease Treatment Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. Pricing Analysis
3.7. Forecast Scenario
3.8. Parent Market Overview
3.9. PEST Analysis
3.10. Porter's Five Forces Analysis
3.11. Key Regulations
3.11.1. Key Regulations - North America
3.11.2. Key Regulations - Latin America
3.11.3. Key Regulations - Europe
3.11.4. Key Regulations - Asia Pacific
3.11.5. Key Regulations - Middle East & Africa
3.12. Product Approvals in Rare Inflammatory Disease Treatment Market
3.13. Investment Feasibility Index
3.14. Market Competition Structure
3.15. Market Positioning and Behaviour Assessment
3.16. List of Distributors
3.17. Key Participants Market Presence (Intensity Map) By Region
4. Global Rare Inflammatory Disease Treatment Market Analysis and Forecast 2012-2026
4.1. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Indication, 2012-2026
4.1.1. Ulcerative Colitis Market Size and Forecast, 2012-2026
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Juvenile Rheumatoid Arthritis Market Size and Forecast, 2012-2026
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Psoriatic Arthritis Market Size and Forecast, 2012-2026
4.1.3.1. Revenue (US$ Mn) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
4.1.4. Other Indications Market Size and Forecast, 2012-2026
4.1.4.1. Revenue (US$ Mn) Comparison, By Region
4.1.4.2. Market Share Comparison, By Region
4.1.4.3. Y-o-Y growth Comparison, By Region
4.2. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Drug Class, 2012-2026
4.2.1. Biologics Market Size and Forecast, 2012-2026
4.2.1.1. Revenue (US$ Mn) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Organic Compounds Market Size and Forecast, 2012-2026
4.2.2.1. Revenue (US$ Mn) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.3. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Mode of Administration, 2012-2026
4.3.1. Injectables Market Size and Forecast, 2012-2026
4.3.1.1. Revenue (US$ Mn) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Oral Market Size and Forecast, 2012-2026
4.3.2.1. Revenue (US$ Mn) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Others Market Size and Forecast, 2012-2026
4.3.3.1. Revenue (US$ Mn) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region
4.4. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Distribution Channel, 2012-2026
4.4.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
4.4.1.1. Revenue (US$ Mn) Comparison, By Region
4.4.1.2. Market Share Comparison, By Region
4.4.1.3. Y-o-Y growth Comparison, By Region
4.4.2. Retail Pharmacies Market Size and Forecast, 2012-2026
4.4.2.1. Revenue (US$ Mn) Comparison, By Region
4.4.2.2. Market Share Comparison, By Region
4.4.2.3. Y-o-Y growth Comparison, By Region
4.4.4. Market Size and Forecast, 2012-2026
4.4.4.1. Revenue (US$ Mn) Comparison, By Region
4.4.4.2. Market Share Comparison, By Region
4.4.4.3. Y-o-Y growth Comparison, By Region
5. North America Rare Inflammatory Disease Treatment Market Size and Forecast, 2012-2026
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Mn) Comparison, By Country
5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Indication
5.6. Revenue (US$ Mn) Comparison, By Drug Class
5.7. Revenue (US$ Mn) Comparison, By Mode of Administration
5.8. Revenue (US$ Mn) Comparison, By Distribution Channel
6. Latin America Rare Inflammatory Disease Treatment Market Size and Forecast, 2012-2026
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Mn) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Indication
6.6. Revenue (US$ Mn) Comparison, By Drug Class
6.7. Revenue (US$ Mn) Comparison, By Mode of Administration
6.8. Revenue (US$ Mn) Comparison, By Distribution Channel
7. Europe Rare Inflammatory Disease Treatment Market Size and Forecast, 2012-2026
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Mn) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
7.4.2. U.K. Market Size and Forecast (US$ Mn), 2012-2026
7.4.3. Spain Market Size and Forecast (US$ Mn), 2012-2026
7.4.4. France Market Size and Forecast (US$ Mn), 2012-2026
7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Indication
7.6. Revenue (US$ Mn) Comparison, By Drug Class
7.7. Revenue (US$ Mn) Comparison, By Mode of Administration
7.8. Revenue (US$ Mn) Comparison, By Distribution Channel
8. Japan Rare Inflammatory Disease Treatment Market Size and Forecast, 2012-2026
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Indication
8.6. Revenue (US$ Mn) Comparison, By Drug Class
8.7. Revenue (US$ Mn) Comparison, By Mode of Administration
8.8. Revenue (US$ Mn) Comparison, By Distribution Channel
9. APEJ Rare Inflammatory Disease Treatment Market Size and Forecast, 2012-2026
9.1. APEJ Outlook
9.2. APEJ Parent Market Outlook
9.3. APEJ Target Market Outlook
9.4. Revenue (US$ Mn) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
9.4.3. Malaysia Market Size and Forecast (US$ Mn), 2012-2026
9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Indication
9.6. Revenue (US$ Mn) Comparison, By Drug Class
9.7. Revenue (US$ Mn) Comparison, By Mode of Administration
9.8. Revenue (US$ Mn) Comparison, By Distribution Channel
10. MEA Rare Inflammatory Disease Treatment Market Size and Forecast, 2012-2026
10.1. MEA Outlook
10.2. MEA Parent Market Outlook
10.3. MEA Target Market Outlook
10.4. Revenue (US$ Mn) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
10.4.3. Israel Market Size and Forecast (US$ Mn), 2012-2026
10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Indication
10.6. Revenue (US$ Mn) Comparison, By Drug Class
10.7. Revenue (US$ Mn) Comparison, By Mode of Administration
10.8. Revenue (US$ Mn) Comparison, By Distribution Channel
11. Global Rare Inflammatory Disease Treatment Market Company Share, Competition Landscape and Company Profiles
11.1. Global Rare Inflammatory Disease Treatment Market- Company Share Analysis
11.2. Global Rare Inflammatory Disease Treatment Market - Competition Landscape
11.3. Global Rare Inflammatory Disease Treatment Market - Company Profiles
11.3.1. Pfizer, Inc.
11.3.2. Novartis AG
11.3.3. Allergan Plc
11.3.4. Abbvie, Inc.
11.3.5. Valeant Pharmaceuticals International, Inc.
11.3.6. Abbott Laboratories
11.3.7. Johnson & Johnson
11.3.8. Regeneron Pharmaceuticals, Inc.
11.3.9. Mallinckrodt Plc
11.3.10. Swedish Orphan Biovitrum AB

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report